JP2017510661A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017510661A5 JP2017510661A5 JP2017504616A JP2017504616A JP2017510661A5 JP 2017510661 A5 JP2017510661 A5 JP 2017510661A5 JP 2017504616 A JP2017504616 A JP 2017504616A JP 2017504616 A JP2017504616 A JP 2017504616A JP 2017510661 A5 JP2017510661 A5 JP 2017510661A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- formula
- antibody
- methyl
- drug conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- LSHWLXVHVUSFGB-KRLZFLGXSA-N CC[C@H](C)[C@@H](C(N(CC)[C@H](C[C@H](c1nc(C(N[C@H](CC2C(O)=O)Cc(cc3)c2cc3NC([C@H](CCCNC(N)=O)NC([C@H](C(C)C)NC(CCCCCN(C(C=C2)=O)C2=O)=O)=O)=O)=O)c[s]1)OC(C)=O)C(C)C)=O)NC(C[C@@H]1N(C)CC[C@@H](C)C1)=O Chemical compound CC[C@H](C)[C@@H](C(N(CC)[C@H](C[C@H](c1nc(C(N[C@H](CC2C(O)=O)Cc(cc3)c2cc3NC([C@H](CCCNC(N)=O)NC([C@H](C(C)C)NC(CCCCCN(C(C=C2)=O)C2=O)=O)=O)=O)=O)c[s]1)OC(C)=O)C(C)C)=O)NC(C[C@@H]1N(C)CC[C@@H](C)C1)=O LSHWLXVHVUSFGB-KRLZFLGXSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461978460P | 2014-04-11 | 2014-04-11 | |
| US61/978,460 | 2014-04-11 | ||
| PCT/US2015/025235 WO2015157594A1 (en) | 2014-04-11 | 2015-04-10 | Tubulysin derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017510661A JP2017510661A (ja) | 2017-04-13 |
| JP2017510661A5 true JP2017510661A5 (cg-RX-API-DMAC7.html) | 2018-05-24 |
Family
ID=54264545
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017504616A Pending JP2017510661A (ja) | 2014-04-11 | 2015-04-10 | ツブリシン誘導体 |
Country Status (19)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA032203B1 (ru) | 2014-04-11 | 2019-04-30 | МЕДИММЬЮН ЭлЭлСи | Производные тубулизина |
| KR20160143808A (ko) | 2014-04-11 | 2016-12-14 | 메디뮨 엘엘씨 | 이중특이적 her2 항체 |
| EA201791896A1 (ru) * | 2015-02-25 | 2018-02-28 | Уильям Марш Райс Юниверсити | Дезацетокситубулизин н и его аналоги |
| WO2017083451A1 (en) | 2015-11-10 | 2017-05-18 | Medimmune, Llc | Binding molecules specific for asct2 and uses thereof |
| AU2016363013B2 (en) | 2015-12-04 | 2022-03-10 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| WO2017134547A1 (en) * | 2016-02-01 | 2017-08-10 | Pfizer Inc. | Tubulysin analogs and methods for their preparation |
| PE20190353A1 (es) | 2016-04-15 | 2019-03-07 | Macrogenics Inc | Moleculas de union b7-h3 novedosas, conjugados anticuerpo-farmaco de los mismos y metodos de uso de los mismos |
| CN109862919A (zh) | 2016-10-11 | 2019-06-07 | 免疫医疗有限公司 | 抗体-药物缀合物联合免疫介导的治疗剂 |
| JP7150820B2 (ja) | 2017-08-01 | 2022-10-11 | メディミューン，エルエルシー | Ｂｃｍａモノクローナル抗体薬剤コンジュゲート |
| EA202091217A1 (ru) * | 2017-12-31 | 2020-09-18 | Ханчжоу Дак Байотек Ко. Лтд | Конъюгат аналога тубулизина с разветвленными линкерами |
| CN109456212A (zh) * | 2018-12-03 | 2019-03-12 | 康化（上海）新药研发有限公司 | 一种沙库比曲中间体的合成方法 |
| MY208067A (en) | 2018-12-21 | 2025-04-11 | Regeneron Pharma | Tubulysins and protein-tubulysin conjugates |
| TWI753252B (zh) * | 2019-05-03 | 2022-01-21 | 中國大陸商杭州多禧生物科技有限公司 | 含支鏈連接體的Ｔｕｂｕｌｙｓｉｎ同系物偶聯物 |
| EA202290091A1 (ru) * | 2019-06-24 | 2022-03-24 | Ханчжоу Дэк Биотек Ко., Лтд | Конъюгат цитотоксического агента с клеточно-связывающей молекулой с разветвленными линкерами |
| AU2021296449A1 (en) * | 2020-06-24 | 2023-01-19 | Regeneron Pharmaceuticals, Inc. | Tubulysins and protein-tubulysin conjugates |
| CN116829592A (zh) | 2020-09-11 | 2023-09-29 | 免疫医疗有限公司 | 治疗性b7-h4结合分子 |
| CA3237211A1 (en) | 2021-11-10 | 2023-05-19 | Astrazeneca Ab | Antibody molecules and conjugates |
| GB202117928D0 (en) | 2021-12-11 | 2022-01-26 | Cancer Research Tech Ltd | Immunotherapy for cancer |
| KR20250029133A (ko) | 2022-06-27 | 2025-03-04 | 아스트라제네카 아베 | 암 치료를 위한 표피성장인자 수용체 티로신 키나제 억제제를 포함하는 조합물 |
| WO2025078841A2 (en) | 2023-10-11 | 2025-04-17 | Antikor Biopharma Limited | Antibodies, conjugates, and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7064211B2 (en) * | 2002-03-22 | 2006-06-20 | Eisai Co., Ltd. | Hemiasterlin derivatives and uses thereof |
| WO2006063135A2 (en) * | 2004-12-09 | 2006-06-15 | Eisai R & D Management Co., Ltd. | Tubulin isotype screnning in cancer therapy using hemiasterlin analogs |
| IT1394860B1 (it) * | 2009-07-22 | 2012-07-20 | Kemotech S R L | Composti farmaceutici |
| US8394922B2 (en) * | 2009-08-03 | 2013-03-12 | Medarex, Inc. | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof |
| EP2780039B9 (en) * | 2011-11-17 | 2018-04-18 | Pfizer Inc | Cytotoxic peptides and antibody drug conjugates thereof |
| SG11201402686UA (en) * | 2011-12-05 | 2014-06-27 | Igenica Inc | Antibody-drug conjugates and related compounds, compositions, and methods |
| BR112015019432A2 (pt) * | 2013-02-14 | 2017-08-22 | Bristol Myers Squibb Co | Compostos de tubulisina, métodos de produção e uso |
| EA032203B1 (ru) * | 2014-04-11 | 2019-04-30 | МЕДИММЬЮН ЭлЭлСи | Производные тубулизина |
| KR20160143808A (ko) * | 2014-04-11 | 2016-12-14 | 메디뮨 엘엘씨 | 이중특이적 her2 항체 |
| WO2015155345A1 (en) * | 2014-04-11 | 2015-10-15 | Medimmune Limited | Antibodies and antibody-drug conjugates |
-
2015
- 2015-04-10 EA EA201691963A patent/EA032203B1/ru not_active IP Right Cessation
- 2015-04-10 WO PCT/US2015/025235 patent/WO2015157594A1/en not_active Ceased
- 2015-04-10 CN CN201580031041.XA patent/CN106458942A/zh active Pending
- 2015-04-10 CA CA2945318A patent/CA2945318A1/en not_active Abandoned
- 2015-04-10 TW TW104111700A patent/TW201625662A/zh unknown
- 2015-04-10 SG SG11201608203RA patent/SG11201608203RA/en unknown
- 2015-04-10 JP JP2017504616A patent/JP2017510661A/ja active Pending
- 2015-04-10 AR ARP150101089A patent/AR100006A1/es unknown
- 2015-04-10 MX MX2016013373A patent/MX2016013373A/es unknown
- 2015-04-10 AU AU2015243379A patent/AU2015243379B2/en not_active Ceased
- 2015-04-10 EP EP15777523.0A patent/EP3129362A4/en not_active Withdrawn
- 2015-04-10 MA MA039862A patent/MA39862A/fr unknown
- 2015-04-10 US US14/683,196 patent/US9427479B2/en not_active Expired - Fee Related
- 2015-04-10 KR KR1020167031176A patent/KR20160142392A/ko not_active Withdrawn
- 2015-04-10 UY UY0001036075A patent/UY36075A/es not_active Application Discontinuation
- 2015-04-10 NZ NZ725131A patent/NZ725131A/en not_active IP Right Cessation
-
2016
- 2016-08-08 US US15/230,918 patent/US10159745B2/en not_active Expired - Fee Related
- 2016-09-14 IL IL247822A patent/IL247822A0/en unknown
- 2016-10-06 CL CL2016002548A patent/CL2016002548A1/es unknown
- 2016-10-07 PH PH12016501995A patent/PH12016501995A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017510661A5 (cg-RX-API-DMAC7.html) | ||
| RU2017117664A (ru) | Комбинация | |
| RU2016109811A (ru) | Лечение рака комбинацией антагониста pd-1 и динациклиба | |
| NZ604007A (en) | Monoclonal antibodies against her2 epitope | |
| JP2018070648A5 (cg-RX-API-DMAC7.html) | ||
| JP2017506227A5 (cg-RX-API-DMAC7.html) | ||
| JP2018530554A5 (cg-RX-API-DMAC7.html) | ||
| RU2014138474A (ru) | Новые модуляторы и способы применения | |
| CY1122456T1 (el) | Μονοκλωνικα αντισωματα εναντιον παραγοντα 15 αυξησης και διαφοροποιησης (gdf-15), και χρησεις αυτων για θεραπευτικη αγωγη καρκινικης καχεξιας και καρκινου | |
| FI3348571T3 (fi) | Yksidomeeninen vasta-aine ohjelmoitu solukuolema -ligandille (pd-l1) ja siitä peräisin oleva proteiini | |
| RU2016146993A (ru) | Комбинация антитела к CCR4 и агониста 4-1BB для лечения рака | |
| MX2017012965A (es) | Anticuerpo anti-c-met y conjugado de farmaco citotoxico de anticuerpo anti-c-met y uso farmaceutico del mismo. | |
| TW200735889A (en) | Method for treating joint damage | |
| IL292193B2 (en) | Anti-b7-h1 antibodies for treating tumors | |
| JP2017506217A5 (cg-RX-API-DMAC7.html) | ||
| RU2016150650A (ru) | Комбинированная терапия для лечения рака | |
| JP2018512443A5 (cg-RX-API-DMAC7.html) | ||
| JP2016523810A5 (cg-RX-API-DMAC7.html) | ||
| JP2018504418A5 (cg-RX-API-DMAC7.html) | ||
| JP2014530215A5 (cg-RX-API-DMAC7.html) | ||
| JOP20210044A1 (ar) | الأجسام المضادة لـ cd38 | |
| JP2012500814A5 (cg-RX-API-DMAC7.html) | ||
| RU2019102009A (ru) | Специфические антитела к pd-l1 и способы их применения | |
| JP2017506234A5 (cg-RX-API-DMAC7.html) | ||
| JP2014205674A5 (cg-RX-API-DMAC7.html) |